The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK.

Autor: Vasiliadou I; Guy's and St. Thomas NHS Foundation Trust, London, UK.; King's College London, London, UK., Grose D; Beatson West of Scotland Cancer Centre, Glasgow, UK., Wilson C; Beatson West of Scotland Cancer Centre, Glasgow, UK., Thapa A; Beatson West of Scotland Cancer Centre, Glasgow, UK., Donnelly O; Portsmouth Hospitals NHS Trust, Portsmouth, Hampshire, UK., Lee E; Guy's and St. Thomas NHS Foundation Trust, London, UK.; King's College London, London, UK., Leslie I; Royal Marsden NHS Foundation Trust, London, UK., Karim M; Royal Marsden NHS Foundation Trust, London, UK., Hartley A; Queen Elizabeth Hospital Birmingham, Birmingham, UK., Partridge S; Imperial College Healthcare NHS Trust-Charing Cross Hospital, London, UK., Medlow K; Imperial College Healthcare NHS Trust-Charing Cross Hospital, London, UK., De Boisanger J; Imperial College Healthcare NHS Trust-Charing Cross Hospital, London, UK., Metcalf R; The Christie NHS Foundation Trust, Manchester, UK., Williamson A; The Christie NHS Foundation Trust, Manchester, UK., Haridass A; The Clatterbridge Cancer Centre, Liverpool, UK., Noble D; Edinburgh Cancer Centre, Edinburgh, UK., Mactier K; Edinburgh Cancer Centre, Edinburgh, UK., Walter H; University Hospitals of Leicester, Leicester, UK., Ma N; University Hospitals of Leicester, Leicester, UK., De Winton E; Royal United Hospitals Bath-NHS Foundation trust, Bath, UK., Cohen J; Royal United Hospitals Bath-NHS Foundation trust, Bath, UK., Rayner L; Royal United Hospitals Bath-NHS Foundation trust, Bath, UK., Geropantas K; Norfolk and Norwich University Hospital, Norwich, UK., Jankowska P; Musgrove Park Hospital-Taunton and Somerset NHS Foundation Trust, Taunton, UK., Mason J; Musgrove Park Hospital-Taunton and Somerset NHS Foundation Trust, Taunton, UK., Moleron R; Aberdeen Royal Infirmary-NHS Grampian, Aberdeen, UK., Laws K; Aberdeen Royal Infirmary-NHS Grampian, Aberdeen, UK., Ulahannan D; St. James's University Hospital, Leeds, UK., Nallathambi C; St. James's University Hospital, Leeds, UK., Michaelidou A; Maidstone Hospital-Tunbridge Wells Hospital-NHS Trust, Tunbridge Wells, UK., Nallamilli S; Maidstone Hospital-Tunbridge Wells Hospital-NHS Trust, Tunbridge Wells, UK., Raouf S; St Bartholomew's Hospital, Barts Health NHS Trust, London, UK., Palmer K; King's College London, London, UK.; St Bartholomew's Hospital, Barts Health NHS Trust, London, UK., Bienz M; Mount Vernon Cancer Centre, London, UK., Karet T; Mount Vernon Cancer Centre, London, UK., Khalique S; Mount Vernon Cancer Centre, London, UK., Paterson C; Beatson West of Scotland Cancer Centre, Glasgow, UK., Harrington K; Royal Marsden NHS Foundation Trust, London, UK.; The Institute of Cancer Research, London, UK., Bhide S; Royal Marsden NHS Foundation Trust, London, UK.; The Institute of Cancer Research, London, UK., Kong A; Guy's and St. Thomas NHS Foundation Trust, London, UK.; King's College London, London, UK.

Publikováno v: International journal of cancer [Int J Cancer] 2024 Sep 01; Vol. 155 (5), pp. 883-893. Date of Electronic Publication: 2024 Apr 29.

Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.

Autor: Nutting C; Head and Neck Unit, The Royal Marsden Hospital, London, UK; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK. Electronic address: chris.nutting@rmh.nhs.uk., Finneran L; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK., Roe J; Department of Speech, Voice and Swallowing, The Royal Marsden Hospital, London, UK; Department of Surgery and Cancer, Imperial College, London, UK., Sydenham MA; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK., Beasley M; Bristol Cancer Institute, United Hospitals Bristol, Bristol, UK., Bhide S; Head and Neck Unit, The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK., Boon C; Oncology Department, The Royal Wolverhampton NHS Trust, Wolverhampton, UK., Cook A; Gloucestershire Oncology Centre, Cheltenham General Hospital, Cheltenham, UK., De Winton E; Department of Oncology, Royal United Hospital Bath, Bath, UK., Emson M; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK., Foran B; Department of Oncology, Weston Park Hospital, Sheffield, UK., Frogley R; Patient and Carer's Advisory Group, The Royal Marsden Hospital, London, UK., Petkar I; Guys Cancer Centre, Guys and St Thomas' Hospital, London, UK., Pettit L; Lingen Davies Cancer Centre, Royal Shrewsbury Hospital, Shrewsbury, UK., Rooney K; Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, UK., Roques T; Clinical Oncology, Norfolk and Norwich University Hospital, Norwich, UK., Srinivasan D; Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK., Tyler J; Department of Physics, The Royal Marsden Hospital, London, UK., Hall E; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2023 Aug; Vol. 24 (8), pp. 868-880. Date of Electronic Publication: 2023 Jul 06.

926P UK national real-world outcome data of first-line pembrolizumab treatment in head and neck squamous cell cancer (HNSCC)

Autor: Vasiliadou, I., Grose, D., Hartley, A., Partridge, S., Haridass, A., Williamson, A., Noble, D., Walter, H., De Winton, E., Cohen, J., Geropantas, K., Donnelly, O., Jankowska, P., Moleron, R., Ulahannan, D., Michaelidou, A., Raouf, S., Khalique, S., Bhide, S., Kong, A.

Publikováno v: In Annals of Oncology October 2023 34 Supplement 2:S584-S584

Inhibition of WEE1 Is Effective in TP53 - and RAS -Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring.

Autor: Seligmann JF; Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom., Fisher DJ; MRC Clinical Trials Unit at UCL, London, United Kingdom., Brown LC; MRC Clinical Trials Unit at UCL, London, United Kingdom., Adams RA; Centre for Trials Research University and Velindre NHS Trust, Cardiff, United Kingdom., Graham J; Beatson Hospital, Glasgow, United Kingdom., Quirke P; Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom., Richman SD; Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom., Butler R; Bristol Genetics Laboratory, Bristol, United Kingdom., Domingo E; MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom., Blake A; MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom., Yates E; MRC Clinical Trials Unit at UCL, London, United Kingdom., Braun M; Christie Hospital, Manchester, United Kingdom., Collinson F; Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom., Jones R; School of Medicine, Cardiff University, Cardiff, United Kingdom., Brown E; Western General Hospital, Edinburgh, United Kingdom., de Winton E; Royal United Hospital, Bath, United Kingdom., Humphrey TC; MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom., Parmar M; MRC Clinical Trials Unit at UCL, London, United Kingdom., Kaplan R; MRC Clinical Trials Unit at UCL, London, United Kingdom., Wilson RH; Beatson Hospital, Glasgow, United Kingdom., Seymour M; Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom., Maughan TS; MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Nov 20; Vol. 39 (33), pp. 3705-3715. Date of Electronic Publication: 2021 Sep 18.

The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer.

Autor: de Winton, E.¹, Heriot, A. G.² alexander.heriot@petermac.org, Ng, M.³, Hicks, R. J.^4,5, Hogg, A.⁴, Milner, A.⁶, Leong, T.^3,5, Fay, M.³, MacKay, J.², Drummond, E.⁴, Ngan, S. Y.^3,5, Winton, E de¹ (AUTHOR)

Publikováno v: British Journal of Cancer. 3/10/2009, Vol. 100 Issue 5, p693-700. 8p. 2 Black and White Photographs, 3 Charts, 4 Graphs.